125 related articles for article (PubMed ID: 24126359)
1. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
Saitoh R; Nagayasu M; Shibahara N; Ono N; Suda A; Kato M; Ishigai M
Drug Metab Pharmacokinet; 2014; 29(2):185-91. PubMed ID: 24126359
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
3. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC
J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
[TBL] [Abstract][Full Text] [Related]
6. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
[TBL] [Abstract][Full Text] [Related]
7. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
9. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
12. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
Yamazaki S; Nguyen L; Vekich S; Shen Z; Yin MJ; Mehta PP; Kung PP; Vicini P
J Pharmacol Exp Ther; 2011 Sep; 338(3):964-73. PubMed ID: 21680888
[TBL] [Abstract][Full Text] [Related]
14. Identification of new biomarkers for clinical trials of Hsp90 inhibitors.
Zhang H; Chung D; Yang YC; Neely L; Tsurumoto S; Fan J; Zhang L; Biamonte M; Brekken J; Lundgren K; Burrows F
Mol Cancer Ther; 2006 May; 5(5):1256-64. PubMed ID: 16731758
[TBL] [Abstract][Full Text] [Related]
15. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
16. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
[TBL] [Abstract][Full Text] [Related]
17. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
Smith-Jones PM; Solit DB; Akhurst T; Afroze F; Rosen N; Larson SM
Nat Biotechnol; 2004 Jun; 22(6):701-6. PubMed ID: 15133471
[TBL] [Abstract][Full Text] [Related]
18. Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.
van de Ven SM; Elias SG; Chan CT; Miao Z; Cheng Z; De A; Gambhir SS
Clin Cancer Res; 2012 Feb; 18(4):1073-81. PubMed ID: 22235098
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
20. Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum.
Meyer KJ; Caton E; Shapiro TA
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]